The DCC protein and prognosis in colorectal cancer

David Shibata, Michael A. Reale, Philip Lavin, Mark Silverman, Eric R. Fearon, Glenn Steele, John M. Jessup, Massimo Loda, Ian C. Summerhayes

Research output: Contribution to journalArticle

257 Citations (Scopus)

Abstract

Background: Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in collorectal carcinoma. Methods: The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III collorectal carcinomas. The Cox proportional hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results: The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III collorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03). Conclusions: DCC is a prognostic marker in patients with stage II or stage III collorectal cancer. In stage II collorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of patients.

Original languageEnglish (US)
Pages (from-to)1727-1732
Number of pages6
JournalNew England Journal of Medicine
Volume335
Issue number23
DOIs
StatePublished - Dec 5 1996

Fingerprint

Colorectal Neoplasms
Proteins
Neoplasms
Carcinoma
Survival Rate
Loss of Heterozygosity
Neoplasm Genes
Proportional Hazards Models
Paraffin
Chromosomes
Survival
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Shibata, D., Reale, M. A., Lavin, P., Silverman, M., Fearon, E. R., Steele, G., ... Summerhayes, I. C. (1996). The DCC protein and prognosis in colorectal cancer. New England Journal of Medicine, 335(23), 1727-1732. https://doi.org/10.1056/NEJM199612053352303

The DCC protein and prognosis in colorectal cancer. / Shibata, David; Reale, Michael A.; Lavin, Philip; Silverman, Mark; Fearon, Eric R.; Steele, Glenn; Jessup, John M.; Loda, Massimo; Summerhayes, Ian C.

In: New England Journal of Medicine, Vol. 335, No. 23, 05.12.1996, p. 1727-1732.

Research output: Contribution to journalArticle

Shibata, D, Reale, MA, Lavin, P, Silverman, M, Fearon, ER, Steele, G, Jessup, JM, Loda, M & Summerhayes, IC 1996, 'The DCC protein and prognosis in colorectal cancer', New England Journal of Medicine, vol. 335, no. 23, pp. 1727-1732. https://doi.org/10.1056/NEJM199612053352303
Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G et al. The DCC protein and prognosis in colorectal cancer. New England Journal of Medicine. 1996 Dec 5;335(23):1727-1732. https://doi.org/10.1056/NEJM199612053352303
Shibata, David ; Reale, Michael A. ; Lavin, Philip ; Silverman, Mark ; Fearon, Eric R. ; Steele, Glenn ; Jessup, John M. ; Loda, Massimo ; Summerhayes, Ian C. / The DCC protein and prognosis in colorectal cancer. In: New England Journal of Medicine. 1996 ; Vol. 335, No. 23. pp. 1727-1732.
@article{af017fc0f89744d5923f4362d52e2d5e,
title = "The DCC protein and prognosis in colorectal cancer",
abstract = "Background: Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in collorectal carcinoma. Methods: The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III collorectal carcinomas. The Cox proportional hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results: The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III collorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03). Conclusions: DCC is a prognostic marker in patients with stage II or stage III collorectal cancer. In stage II collorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of patients.",
author = "David Shibata and Reale, {Michael A.} and Philip Lavin and Mark Silverman and Fearon, {Eric R.} and Glenn Steele and Jessup, {John M.} and Massimo Loda and Summerhayes, {Ian C.}",
year = "1996",
month = "12",
day = "5",
doi = "10.1056/NEJM199612053352303",
language = "English (US)",
volume = "335",
pages = "1727--1732",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - The DCC protein and prognosis in colorectal cancer

AU - Shibata, David

AU - Reale, Michael A.

AU - Lavin, Philip

AU - Silverman, Mark

AU - Fearon, Eric R.

AU - Steele, Glenn

AU - Jessup, John M.

AU - Loda, Massimo

AU - Summerhayes, Ian C.

PY - 1996/12/5

Y1 - 1996/12/5

N2 - Background: Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in collorectal carcinoma. Methods: The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III collorectal carcinomas. The Cox proportional hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results: The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III collorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03). Conclusions: DCC is a prognostic marker in patients with stage II or stage III collorectal cancer. In stage II collorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of patients.

AB - Background: Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer. Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate. We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in collorectal carcinoma. Methods: The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II or III collorectal carcinomas. The Cox proportional hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy. Results: The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III collorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001). In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P=0.03). Conclusions: DCC is a prognostic marker in patients with stage II or stage III collorectal cancer. In stage II collorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers. These findings may thus have therapeutic implications in this group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0029955460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029955460&partnerID=8YFLogxK

U2 - 10.1056/NEJM199612053352303

DO - 10.1056/NEJM199612053352303

M3 - Article

VL - 335

SP - 1727

EP - 1732

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -